Skip to content
thestock.space

Panchsheel Organics (BSE: PANCHSHEEL) had a P/E of 13.6× on 6 Nov 2026, below the industry P/E of 28.7×, and the shares are 31% below their 52-week high. Sales grew 1.3% a year over 3 years while net profit fell 8.4%; its ROCE of 10% is the second-lowest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. It carries very little debt, and its dividend yield is 3.0%. It is a small-cap company with a market cap of ₹110 Cr, ranked 117th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 24% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹110.00
Day high
₹110.00
Day low
₹103.30
Prev. close
₹106.57
Volume
2.3 L

Health check

1 good · 1 fair · 4 to check
  • ReturnsBehind

    −23.9% over a year, better than 0 of 7 peers.

  • Price tagCheaper

    P/E 13.6 vs industry 28.7.

  • GrowthSlow

    Sales +1.3%, profit −8.4% a year over 3 years.

  • ProfitabilityWeak

    ROCE 10.0% vs peer median 17.9%.

  • Balance sheetFair

    Practically debt-free, Piotroski 4 of 9.

  • Red flags3 to check

    Return on equity is low at 7.9%.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹110 Cr, #117 of 154 in its industry by size.

Defensive

Beta 0.21 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹108 Cr · profit ₹10 Cr
Market cap
₹110 Cr
Small cap
P/E
13.6
Industry 28.7
Price to book
0.99
Peers 4.99
Dividend yield
3.00%
ROE
7.9%
Peers 14.7%
ROCE
10.0%
Peers 17.9%
Debt to equity
0.04
Debt ₹5.65 Cr
EPS (TTM)
₹7.82
OPM (TTM)
12.1%
Net margin 9.5%
Sales growth
+4.7%
Latest quarter vs a year ago
Profit growth
−18.7%
Latest quarter vs a year ago
Price to sales
1.02
EV/EBITDA 10.8

Strengths and risks

Strengths

  • Practically debt-free.
  • Dividend yield of 3.00%.
  • P/E of 13.6 against an industry P/E of 28.7.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Return on equity is low at 7.9%.
  • Quarterly profit down 18.7% on a year ago.
  • 31% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Panchsheel Organics

Panchsheel Organics Limited engages in the manufacture and trade of bulk drugs and intermediates in India and internationally. The company manufactures and exports active pharma ingredients (API), human and veterinary intermediates and finished formulations, specialty chemicals, nutraceuticals, vitamins hormones, agri biotech range, aqua culture, dehydrated culture media, finished formulations, and steroids, etc. It also provides a range of products in…

Headquarters
Mumbai
Employees
191
Sector
Healthcare
ISIN
INE316G01019
Website
panchsheelorganics.com

Price range

52 weeks

₹86.10₹154.40

Today

₹103.30₹110.00
Avg volume (3M)
8K
1-year return
minus 23.9%
From 52-week high
minus 31.3%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.87%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.30%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.81%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.59%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.93%minus 6.6%
PANCHSHEELPanchsheel Organics106.02minus 0.52%11013.60.9910.0%7.9%12.1%1.3%−8.4%3.00%minus 23.9%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.59%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26
23.625.326.731.124.7
19.821.82328.621.3
3.73.53.82.43.3
15.9%13.8%14.1%7.8%13.5%
0.70.61.11.30.5
0.10.10.100.1
0.60.60.60.60.6
3.83.54.233.1
25.0%25.1%11.4%44.1%25.8%
2.82.63.71.72.3
2.161.982.791.291.76

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+1.3%
Profit CAGR 3Y
−8.4%
EPS CAGR 3Y
−11.7%
ROE
7.9%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
103105107107
–+2.5%+1.8%minus 0.4%
82.886.289.593.1
19.91917.613.6
19.3%18.0%16.4%12.7%
0.82.32.83.4
0.20.10.10.1
1.61.72.22.3
0.1−0−0–
19.119.418.114.5
26.2%27.2%23.8%25.1%
14.114.113.810.8
–+0.3%minus 2.2%minus 21.5%
11.9410.7110.478.22

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
11.813.213.213.2
84.3112121128
5.66.35.45.6
2127.72425.5
123159163172
11.219.432.737.3
3.55.914.817.1
31.531.735.537.9
3.421.84.23.5
73.180.37676.1
123159163172

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
09.63.810.3
−34.4−7.2−16.3−6.7
35.816−5.2−4.2
1.518.4−17.7−0.6
−4−9.9−15.6−6.9
−3.9−0.3−11.73.4
−3.5−3.5−4−4.2

Shareholding pattern

This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.

Major shareholders

BSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you